New collaboration between Amersham Biosciences and Affibody increases potential in protein purification

Under the agreement, the two companies will work to develop affinity-based products for use in the production processes for protein-based pharmaceuticals. The development of these products will be based on Affibodies™, a novel class of small, robust affinity proteins designed to bind desired protein targets. Financial details of the agreement were not disclosed.

“The use of Affibodies™ opens up new possibilities for large-scale protein purification for production of protein based pharmaceuticals. We are very pleased that we can continue to build value through our successful collaboration with Affibody”, said Peter Ehrenheim, Vice President of Protein Separations at Amersham Biosciences.

Affibody and Amersham Biosciences have a successful ongoing collaboration, which was initiated two years ago. For Amersham Biosciences, the newly initiated collaboration entails an expansion of the Company’s research portfolio regarding products for purification, i.e. affinity chromatography.

“The agreement validates the commercial value of Affibody’s technology and is an important milestone for us. This also shows that Affibody is an attractive business partner. Our collaboration with Amersham Biosciences has been very fruitful so far, and has already resulted in royalty revenues,” says Torben Jørgensen, CEO of Affibody.